Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab CYP interaction study in adults with moderate-to-severe atopic dermatitis
NL-OMON46290Active, not recruiting
- Sponsor
- LEO Pharma
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of tralokinumab in atopic dermatitis (AD), sponsored by LEO Pharma. Primary endpoints: AUClast ratio after multiple-dose tralokinumab versus baseline and Cmax ratio after multiple-dose tralokinumab versus baseline. Started Mar 2019; status: active, not recruiting.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON46290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46290.